



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 39/00, 39/385	A1	(11) International Publication Number: WO 92/13558 (43) International Publication Date: 20 August 1992 (20.08.92)
(21) International Application Number: PCT/US92/00975 (22) International Filing Date: 4 February 1992 (04.02.92)		(81) Designated States: AU, CA, CS, FI, HU, JP, KR, NO, PL, RO, RU.
(30) Priority data: 652,648 8 February 1991 (08.02.91) US		Published <i>With international search report.</i>
(71) Applicant: LA JOLLA PHARMACEUTICAL [US/US]; 6455 Nancy Ridge Drive, Suite 300, San Diego, CA 92121 (US).		
(72) Inventors: BARSTAD, Paul, Aryln ; 1974 Amarillo Place, Escondido, CA 92025 (US). IVERSON, Gilbert, Michael ; 13784 Boquita Drive, Del Mar, CA 92014 (US).		
(74) Agent: CIOTTI, Thomas, E.; Morrison & Foerster, 545 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US).		

(54) Title: A COMPOSITION FOR INDUCING HUMORAL ANERGY

(57) Abstract

Conjugates of stable nonimmunogenic polymers and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	CN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

-1-

5

A COMPOSITION FOR INDUCING HUMORAL ANERGY

Technical Field

10 This invention is in the field of immunology and concerns compositions and methods for inducing humoral anergy for the purpose of treating antibody-mediated pathologies. More specifically, the invention relates to conjugates of nonimmunogenic stable polymers
15 and analogs of immunogens that lack T cell epitopes.

Background of the Invention

20 In order to survive in a world of pathogenic or potentially pathogenic microorganisms, higher organisms have evolved immune systems which can specifically recognize virtually any foreign substance through its characteristic molecules. This recognition frequently results in the production of specific proteins called antibodies which bind only to the foreign substance which
25 induced their synthesis, causing the elimination of the invading microorganism. Occasionally an animal's immune system makes antibodies which recognize some of its own molecules, generating an autoimmune state that may affect the animal's health adversely.

30 The induction of specific antibodies in response to an immunogen involves the interaction of multiple cell types, including thymus-derived lymphocytes (T cells), macrophages, and bone marrow-derived lymphocytes (B cells). B cells possess surface
35 immunoglobulin by which they are able to bind immunogens.

-2-

the first step in their activation and clonal expansion. The site(s), region(s) or domain(s) of the immunogen to which the immunoglobulin binds is called a "B cell epitope". In the second step of B cell activation and 5 expansion, T cells are activated through interaction with the B cell bound-immunogen at a site, region or domain of the immunogen called a "T cell epitope". Once activated, the T cells provide positive signal(s) to the B cells bound by the immunogen and they proceed to differentiate 10 and to produce and secrete antibody. Positive signals from the T cell include the secretion of lymphokines, and/or direct contact between the B cells and T cells. T cell epitopes may be different or more restricted in scope than B cell epitopes. As discussed above, in order 15 for an immunogen to elicit T dependent antibodies, it must have epitopes recognized by both B and T cells.

Past attempts to treat antibody-mediated pathologies have involved both general and specific suppression of the immune response. General suppression 20 has typically employed broad spectrum, nonspecific immunosuppressants such as cyclophosphamide or steroids. Because these nonspecific drugs suppress many aspects of the immune system, they eliminate its required and beneficial functions as well as the malfunction causing 25 the condition being treated. They are thus used with extreme caution if at all, and subject the patient to risk from secondary infections or other undesirable side effects.

Because of the disadvantages of general 30 immunosuppression, methods for specifically suppressing an immune response to an immunogen without affecting the normal functions of the immune system are highly preferred for treating antibody-mediated pathologies. The present invention concerns compositions and methods

-3-

for specifically suppressing the humoral response to immunogens.

Prior attempts to induce specific immunosuppression have focused on conjugating haptens and 5 immunogens to nonimmunogenic polymeric carriers.

Benacerraf, Katz and their colleagues used conjugates of haptens and antigens and copolymers of D-lysine and D-glutamic acid (D-EK). Their initial studies involved conjugates of the synthetic hapten 2,4-dinitrophenyl 10 (DNP) in guinea pigs and mice and showed the conjugates were capable of inducing humoral unresponsiveness. These initial studies were then extended to conjugates of other haptens and conjugates of immunogens. While the results with haptens were repeatable, and although their patents 15 (U.S. 4,191,668 and 4,220,565) allege the approach is effective in inducing tolerance to immunogens, subsequent work has shown that conjugates of D-EK and immunogens do not provide a means for inducing humoral unresponsiveness to the immunogen. For instance, Liu et al., J. Immun. 20 (1979) 123:2456-2464, report that subsequent studies of those conjugates demonstrate that the conjugates "do not induce unresponsiveness at the level of protein specific B cells." Similarly, Butterfield et al., J. Allergy Clin. Immun. (1981) 67:272-278, reported that conjugates 25 of ragweed immunogen and D-EK actually stimulated both IgE and IgG responses to the immunogen.

This subsequent work and other data dealing with conjugates of nonimmunogenic polymers and immunogens (Saski et al., Scand. J. Immun. (1982) 16:191-200; Sehon, 30 Prog. Allergy (1982) 32:161-202; Wilkinson et al., J. Immunol. (987) 139:326-331, and Borel et al., J. Immunol. Methods (1990) 126:159-168) appear to indicate that the anergy, if any, obtained with such conjugates is due to suppression of T cell activity, not B cell 35 unresponsiveness.

-4-

Several other references deal with conjugates of nonimmunogenic polymers and DNA. See U.S. 4,191,668; U.S. 4,650,625; J. Clin. Invest. (1988) 82:1901-1907; and commonly owned U.S. patent application Serial No.

5 07/494,118. As a whole, these references indicate that these DNA conjugates may suppress the production of antibodies to this lupus autoimmunogen. It should be noted in this regard that DNA, like haptens, does not possess T cell epitopes.

10 In sum, applicants believe the prior art shows that antibody production to conjugates of nonimmunogenic stable polymers and haptens or DNA, neither of which have T cell epitopes, may provide B cell unresponsiveness. Applicants also believe that conjugates of immunogens 15 do not provide B cell unresponsiveness but may activate T cells to directly suppress the immune response.

Disclosure of the Invention

20 The present invention resides in the discovery that the failure of the prior conjugates of nonimmunogenic stable polymers and immunogens to induce B cell anergy (unresponsiveness) was due to the fact that the immunogens contained both B and T cell epitopes and 25 that if the latter were eliminated, the conjugate would be effective for inducing B cell anergy.

Accordingly, one aspect of the invention is a composition for inducing specific B cell anergy to an immunogen comprising a conjugate of a nonimmunogenic 30 biologically stable carrier polymer and an analog of the immunogen that (a) binds specifically to B cells to which the immunogen binds and (b) lacks the T cell epitope(s) of the immunogen.

-5-

Pharmaceutical compositions of the above-described conjugates and pharmaceutically acceptable carriers or vehicles are another aspect of the invention.

A further aspect of the invention is a method 5 of inducing specific B cell anergy to an immunogen in an individual comprising administering to the individual an effective amount of the above-described conjugate.

Yet another aspect of the invention is a method of treating an individual for an antibody-mediated 10 pathology in which undesired antibodies are produced in response to an immunogen comprising administering to the individual a therapeutically effective amount of the above-described conjugate.

15 Brief Description of the Drawings

Figure 1 graphically illustrates the detection of B cell epitopes in immunized CAF1 mice as described in Example 1.

20 Figure 2, similarly, illustrates the detection of T cell epitopes as described in Example 1.

Figure 3 illustrates the suppression of antibodies to peptide "L-53" as described in Example 1.

Figures 4 and 5 are graphs of the results 25 described in Example 4.

Modes for Carrying Out the Invention

As used herein the term "B cell anergy" intends unresponsiveness of those B cells requiring T cell help to produce and secrete antibody and includes, without limitation, clonal deletion of immature and/or mature B cells and/or the inability of B cells to produce antibody. "Unresponsiveness" means a therapeutically effective reduction in the humoral response to an immunogen. Quantitatively the reduction (as measured by

-6-

reduction in antibody production) is at least 50%, preferably at least 75%, and most preferably 100%.

"Antibody" means those antibodies which are T cell dependent.

5 As used herein the term "immunogen" means a chemical entity that elicits a humoral immune response when injected into an animal. Immunogens have both B cell epitopes and T cell epitopes.

10 As used herein "individual" denotes a member of the mammalian species and includes humans, primates, domestic animals such as cattle and sheep, sports animals such as horses, and pets such as dogs and cats.

15 The term "analog" of an immunogen intends a molecule that (a) binds specifically to an antibody to which the immunogen binds specifically and (b) lacks T cell epitopes. Although the analog will normally be a fragment or derivative of the immunogen and thus be of the same chemical class as the immunogen (e.g., the immunogen is a polypeptide and the analog is a polypeptide), chemical similarity is not essential. Accordingly, the analog may be of a different chemical class than the immunogen (e.g., the immunogen is a carbohydrate and the analog is a polypeptide) as long as it has the functional characteristics (a) and (b) above.

20 25 The analog may be a protein, carbohydrate, lipid, lipoprotein, glycoprotein, lipopolysaccharide or other biochemical entity. Further, the chemical structure of neither the immunogen nor the analog need be defined for the purposes of this invention.

30 "Nonimmunogenic" is used to describe the carrier polymer means that the carrier polymer elicits substantially no immune response when it is administered by itself to an individual.

35 Immunogens that are involved in antibody mediated pathologies may be external (foreign to the

-7-

individual) immunogens such as biological drugs, allergens, idiopathic contrast media, and the like or self-immunogens (autoimmunogens) such as those associated with thyroiditis (thyroglobulin), stroke (cardiolipin), 5 male infertility (α -sperm), myasthenia gravis (acetylcholine receptor), rheumatic fever (carbohydrate complex), and Rh hemolytic disease (D immunogen).

Analogs to such immunogens may be identified by screening candidate molecules to determine whether they 10 (a) bind specifically to serum antibodies to the immunogen and (b) lack T cell epitopes. Specific binding to serum antibodies may be determined using conventional immunoassays and the presence or absence of T cell epitopes may be determined by conventional T cell activation assays. In this regard an analog which "binds specifically" to serum antibodies to the immunogen exhibits a reasonable affinity thereto. The presence or absence of T cell epitopes may be determined using the tritiated thymidine incorporation assay described in the 15 examples. Analogs that fail to induce statistically significant incorporation of thymidine above background are deemed to lack T cell epitopes. It will be appreciated that the quantitative amount of thymidine incorporation may vary with the immunogen. Typically a 20 stimulation index below about 2-3, more usually about 25 1-2, is indicative of a lack of T cell epitopes.

A normal first step in identifying useful analogs is to prepare a panel or library of candidates to screen. For instance, in the case of protein or peptide 30 analogs, libraries may be made by synthetic or recombinant techniques such as those described by Geysen et al. in Synthetic Peptides as Antigens; Ciba Symposium (1986) 119:131-149; Devlin et al., Science (1990) 35 249:404-406; Scott et al., Science (1990) 249:386-390; and Cwirla et al., PNAS USA (1990) 87:6378-6382. In one

-8-

synthetic technique, peptides of about 5 to 30 amino acids are synthesized in such a manner that each peptide overlaps the next and all linear epitopes are represented. This is accomplished by overlapping both 5 the carboxyl and amino termini by one less residue than that expected for a B cell epitope. For example, if the assumed minimum requirement for a B cell epitope is six amino acids, then each peptide must overlap the neighboring peptides by five amino acids. In this 10 embodiment, each peptide is then screened against antisera produced against the native immunogen, either by immunization of animals or from patients, to identify the presence of B cell epitopes. Those molecules with antibody binding activity are then screened for the 15 presence of T cell epitopes as described in the examples. The molecules lacking T cell epitopes are useful as analogs in the invention.

If the T cell epitope(s) of an immunogen are known or can be identified, random screening of candidate 20 analogs is not necessary. In such instances, the T cell epitope(s) may be altered (e.g., by chemical derivatization, or elimination of one or more components of the epitope) to render them inoperative or be eliminated completely, such as, for instance, in the case 25 of peptides, by synthetic or recombinant procedures.

The analogs are coupled to a nonimmunogenic polymeric carrier to prepare the conjugates of the invention. Preferred polymeric carriers are biologically 30 stable, i.e., they exhibit an in vivo excretion half-life of days to months, and are preferably composed of a synthetic single chain of defined composition. They will normally have a molecular weight in the range of about 5,000 to about 200,000, preferably 5,000 to 30,000. Examples of such polymers are polyethylene glycol, poly- 35 D-lysine, polyvinyl alcohol, polyvinyl pyrrolidone,

-9-

immunoglobulins, and "D-EK", a copolymer of D-glutamic acid and D-lysine. Particularly preferred carrier polymers are D-EKs having a molecular weight of about 5,000 to about 30,000, and an E:K (D-glutamic acid:D-lysine) mole ratio of approximately 60:40, as described in U.S. Patent Application Serial No. 07/494,118, referenced above.

Conjugation of the analog to the carrier polymer may be effected in any number of ways, typically involving one or more crosslinking agents and functional groups on the analog and carrier.

Poly peptide analogs will contain amino acid sidechain groups such as amino, carbonyl, or sulfhydryl groups that will serve as sites for coupling the analog to the carrier. Residues that have such functional groups may be added to the analog if the analog does not already contain same. Such residues may be incorporated by solid phase synthesis techniques or recombinant techniques, both of which are well known in the peptide synthesis arts. In the case of carbohydrate or lipid analogs, functional amino and sulfhydryl groups may be incorporated therein by conventional chemistry. For instance, primary amino groups may be incorporated by reaction with ethylenediamine in the presence of sodium cyanoborohydride and sulfhydryls may be introduced by reaction of cysteamine dihydrochloride followed by reduction with a standard disulfide reducing agent. In a similar fashion the carrier may also be derivatized to contain functional groups if it does not already possess appropriate functional groups. With specific reference to conjugating peptide analogs and D-EK or other proteinaceous carriers, coupling is preferably carried out using a heterobifunctional crosslinker, such as sulfosuccinimidyl(4-iodoacetyl) aminobenzoate, which links the ϵ amino group on the D-lysine residues of D-EK

-10-

to a sulfhydryl side chain from an amino terminal cysteine residue on the peptide to be coupled. This method is preferably carried out such that an average of 3 to 5 analog molecules are coupled to each D-EK molecule 5 and the average molecular weight of the D-EK prior to coupling is 5,000 to 30,000 daltons.

The conjugates will normally be formulated for administration by injection (e.g., intraperitoneally, intramuscularly, etc.). Accordingly, they will typically 10 be combined with pharmaceutically acceptable carriers such as saline, Ringer's solution, dextrose solution, and the like. The conjugate will normally constitute about 0.01% to 10% by weight of the formulation. The conjugate is administered to an individual in a "therapeutically 15 effective amount", i.e., an amount sufficient to produce B cell anergy to the involved immunogen and effect prophylaxis, improvement or elimination of the antibody-mediated condition being addressed. The particular dosage regimen, i.e., dose, timing and repetition, will 20 depend on the particular individual and that individual's medical history. Normally, a dose of about 10 µg to 1 mg conjugate/kg body weight will be given, daily for three consecutive days. Other appropriate dosing schedules would be 3 doses per week, or one dose per week. 25 Repetitive administrations, normally timed according to B cell turnover rates, may be required to achieve and/or maintain a state of humoral anergy. Such repetitive administrations will typically involve treatments of up to 1 mg/kg of body weight every 30 to 60 days, or sooner, 30 if an increase in antibody titer is detected. Alternatively, sustained continuous release formulations of the conjugates may be indicated for some pathologies. Various formulations and devices for achieving sustained release are known in the art.

-11-

Anti-T helper cell treatments may be administered together with the conjugates. Such treatments usually employ agents that suppress T cells such as steroids or cyclosporin.

5 The following examples are intended to further illustrate the invention and its uniqueness. These examples are not intended to limit the scope of the invention in any manner.

10

Example 1

B Cell Anergy to the Acetylcholine Receptor Preparation of Peptides and D-EK/Peptide Conjugates:

15 The α -subunit of the acetylcholine receptor of Torpedo californicus is described by Stroud, R.M., and Finer-Moore, J., Ann. Rev. Cell Biol. (1985) 1:317:351, and Sumikawa, K., et al., Nucl. Acids Res. (1982) 10:5809-22. The peptide defined by residues 47-127 of that α -subunit is called the major immunogenic region
20 (MIR).

25 Two peptides, L-42 and L-53, corresponding to residues 61-77 and 112-127 of that α -subunit, were synthesized using conventional solid-phase methods and purified to homogeneity by HPLC. An amino terminal cysteine was added to each sequence for the purpose of attachment of the peptide to D-EK via a thio ether linkage.

30 Each peptide (40 mg) was dissolved in 0.1M sodium borate buffer, pH 9.0. The solution was reacted with citraconic anhydride (400 μ L) at room temperature; the pH was maintained above 7.0 by addition of 1M NaOH. The solution was then made 20 mM in dithiothreitol and was warmed at 37°C for 20 minutes to reduce the peptide. The mixture was quickly desalting over G-10 Sephadex

-12-

columns which were equilibrated with 0.1M sodium borate, pH 7.0.

D-EK (200 mg, weight average mw = 10,000 - 30,000) was dissolved in 2.0 mL of 0.1M sodium borate.
5 Sulfosuccinimidyl (4-iodoacetyl) aminobenzene (SSIAB, 10 mg, Pierce Chemical) was added to the mixture and the mixture was reacted for 90 minutes at room temperature in the dark. The mixture was then desalted over a 10 mL G-25 column, equilibrated with 0.1M sodium borate,
10 pH 7.0.

The desalted SSIAB-D-EK was mixed with the reduced and desalted peptide and reacted overnight. The resulting conjugate was placed in dialysis tubing with a 14 Kd cutoff and was dialyzed against 5% acetic acid to remove citraconyl groups. The dialysis buffer was changed to phosphate-buffered saline and the dialysis continued.
15

Detection of B cell epitopes:

CAF1 mice were immunized (day 0)
20 intraperitoneally (i.p.) with 50 µg of recombinant torpedo MIR absorbed onto alum plus B. pertussis vaccine (Iverson, G.M., (1986) Handbook of Experimental Immunology, Vol. 2, p. 67, D.M. Weir ed., Blackwell Scientific Publications, Palo Alto, CA). The mice received a booster injection of the same protein in saline, IP, on day 21 and were bled from the tail vein on day 28. Sera from these mice (anti-MIR sera) were used to screen peptides L-42 and L-53 for the presence of B cell epitopes, as follows. The sera were added to
25 microtiter wells coated with 10 µg/ml of the indicated peptide conjugates. The plates were incubated at 37°C for one hour, washed 3 times, 100 µl of alkaline phosphatase-conjugated goat antimouse antibody was added, incubated at 37°C for one hour, washed 3 times, and
30 100 µl of developer (substrate) was added to each well.
35

-13-

The plates were incubated at room temperature for 30 minutes and the amount of color in each well was determined in a Titertek® Multiskan. Results are illustrated graphically in Figure 1. The curve labelled 5 "L42 or L53, NMS" contains the values obtained using normal mouse serum (NMS) instead of the anti-MIR sera on plates coated with either L42 or L53. As shown in Figure 1, both peptides reacted specifically with antibodies from the immunized mice indicating the presence of B cell 10 epitopes on both peptides.

Detection of T cell epitopes:

T cell activation was assayed by the general procedure of Bradley, M.L., (1980) in Mishell and Shigii, eds., Selected Methods in Cellular Immunology (W.H. Freeman and Co., San Francisco, CA), p. 164. CAF1 mice were immunized on the footpad with 50 µg MIR in Complete Freund's Adjuvant (CFA) on day 0. On day 7 the popliteal lymph nodes were removed and placed in culture in microtiter plates using 5×10^5 cells per well. The 15 peptides or peptide-DEK conjugate were added to the cultures, and on day 4, 1 µCi of tritiated thymidine was added to each well to measure proliferation of T cells. The cultures were harvested on day 5 with a Skatron® cell harvester. The amount of incorporated ^3H -thymidine was 20 determined in a Beckman L6800® liquid scintillation counter. The stimulation index was calculated by dividing the CPM incorporated with peptide by the CPM incorporated from cultures without any peptide. A 25 stimulation index > 1 was indicative of the presence of a T cell epitope on the peptide added to the well. As 30 shown in Figure 2, L-42 but not L-53 possessed T cell epitopes in this assay.

-14-

Induction of B Cell Anergy to L-53 by L-53/D-

EK Conjugate:

CAF1 mice were immunized with 50 µg of MIR, i.p., absorbed onto alum plus B. pertussis vaccine on day 0. On days 21, 22 and 23 the mice (6 mice per group) received 10 or 100 µg of either L-42-D-EK conjugate or L-53-D-EK conjugate. One group received only saline. On day 28 all mice received a booster injection of MIR in saline and on day 35 all mice were bled and assayed for the presence of antibodies to L-42 and L-53 in their sera, using an ELISA assay as described above with respect to Figure 1. The results for antibodies to L42 are shown in Figure 3A and for antibodies to L53 are shown in Figure 3B. The L-53 conjugate suppressed antibody formation to L-53 but not to L-42. The L-42 conjugate did not suppress the antibody response to either L-42 or L-53 but rather may have increased antibody production to L-42. The antibody titers are expressed as a percent of a standard sera. The P values were determined by a standard t test comparing each dose to the saline control.

Example 2

Failure of Ovalbumin-D-EK Conjugate to

Induce B Cell Anergy to Ovalbumin

This example is further evidence that conjugates of immunogens and D-EK do not induce B cell anergy.

Synthesis of Ovalbumin-D-EK Conjugate:

Chicken egg ovalbumin (50 mg) was dissolved in 5 mL of 0.1M sodium borate buffer, pH 9.0, containing 10 mM EDTA. After the addition of 3.0 mg of 2-iminothiolane (Traut's reagent), the mixture was reacted for 2.5 hours at room temperature. D-EK (54 mg), dissolved in 0.5M sodium borate, pH 9.0, at a concentration of 100 mg/mL,

-15-

was reacted with SSIAB (18 mg; Pierce Chemical) for 2.5 hours in the dark, at room temperature. The two reaction mixtures described above were desalted separately on G-25 columns (Pharmacia; 10 mL column volume, equilibrated with 0.1M sodium borate, pH 9.0) and the excluded fractions were combined and reacted for 16 hours at 4°C, in the dark. The reaction product was fractionated by gel filtration over Sephadex S-200 (490 mL, Pharmacia) columns, equilibrated with 0.2M ammonium bicarbonate.

5 Fractions containing conjugate, as assessed by polyacrylamide gel electrophoresis, in the presence of sodium dodecyl sulfate (SDS-PAGE), were pooled and dried under vacuum. The dried material was reacted with 0.8 mL of citraconic anhydride, maintaining the pH between 7 and 10

10 Fractions containing conjugate, as assessed by polyacrylamide gel electrophoresis, in the presence of sodium dodecyl sulfate (SDS-PAGE), were pooled and dried under vacuum. The dried material was reacted with 0.8 mL of citraconic anhydride, maintaining the pH between 7 and 9 by the addition of 1M NaOH, in order to efficiently separate conjugated ovalbumin from unreacted protein.

15 The citraconylated conjugate was rechromatographed over S-200, and fractions containing high molecular weight material (> 80,000 daltons), as assessed SDS-PAGE, were used for biological studies.

20

Chicken ovalbumin, when conjugated to D-EK, does not induce B cell anergy in mice immunized to chicken ovalbumin:

Female CAF₁ mice were primed with chicken ovalbumin (ova; 100 µg/mouse, i.p.) precipitated on alum, with B. pertussis vaccine added as an adjuvant. Sixteen weeks later, the mice were divided into two groups of six mice each. One group (control) was treated with saline, and the second group was injected with a conjugate of ova and D-EK (ova-D-EK; 200 µg/mouse/day, i.p.). The mice were dosed on three successive days. One week after the first dose, the mice in both groups were boosted, i.p., with ova in saline (100 µg/mouse). One week later, the mice were bled from a tail vein. The plasma was harvested and assayed for the amount of anti-ova

25

30

35

-16-

antibodies by an ELISA assay. As shown in Table 1, the ova-D-EK conjugate did not suppress the anti-ova response.

5

Table 1

Group	Treatment	Percent of Anti-Ova Standard ¹ Serum ± S.D.
1	saline	70.7 ± 36
2	ova-D-EK	160.2 ± 167

10

- 1 The amount of anti-ova antibody was determined in an ELISA, measured against a standard pool of sera obtained from CAF₁ mice immunized and boosted with ova. The values shown are the mean and standard deviation for the six mice in each group.

15

Example 3

20

Failure of MIR-D-EK Conjugate to Induce B Cell Anergy to MIR

This example is still further evidence that conjugates of immunogens and D-EK do not induce B cell anergy.

25

Synthesis of MIR-D-EK Conjugate:

MIR was modified on its carboxyl-terminus to include a sequence of 8-amino acids (Arg-Ser-Lys-Ser-Lys-Ser-Lys-Cys (SEQ. ID NO.: 1)). The amino-terminus was extended by one amino acid, proline. Purified modified MIR (250 mg) was reduced with 100 mM dithiothreitol and was desalting over Sephadex G-25 (Pharmacia), equilibrated with 0.1 M sodium borate buffer, pH 9.0, containing 10 mM EDTA. D-EK (400 mg) was reacted with SSIAB (29 mg) as in the previous examples. The product was desalting over G-25. The excluded volumes from the modified MIR and D-EK G-25 column runs were

30

35

-17-

combined and reacted at 4°C for 16 hours, in the dark. Excess SSIAB groups were quenched with 2-mercaptoethanol, and the reaction mixture was concentrated to 20 mL over a PM-10 membrane (Amicon Corporation). The mixture was
5 treated with 1.0 mL of citraconic anhydride and chromatographed over S-300 (Pharmacia; 1.8 L), equilibrated with 5% ammonium hydroxide. Fractions containing two or more modified MIR groups per D-EK, as assessed by SDS-PAGE, were pooled and used for biological
10 studies.

MIR-D-EK conjugate contains T cell epitopes in rats immunized with MIR from the same species:

T cell activation was assayed by the general procedure of Bradley, supra. Female Lewis rats were
15 immunized in the footpad with MIR (50 µg) in complete Freund's adjuvant (C) on day 0. On day 7, the popliteal lymph nodes were removed and placed in culture in microtiter plates using $5 \cdot 10^5$ cells per well. MIR-D-EK was added, and, after four days of culture, the wells
20 were pulsed with tritiated thymidine (1-µCi) to measure proliferation of T cells. The cultures were collected after 5 days of culture with a Skatron™ cell harvester. The amount of incorporated ^3H -thymidine was determined by scintillation spectrometry. The stimulation index was
25 calculated by dividing the counts incorporated in the absence of the conjugate. A stimulation index of greater than 1 was considered indicative of the presence of a T cell epitope on the added conjugate. The stimulation index was 4 or greater at all concentrations of MIR-D-EK
30 tested (10 µg/mL to 400 mg/mL). This proves that T cells from MIR-immunized rats recognize T cell epitopes on the MIR-D-EK conjugate in this assay.

-18-

MIR-D-EK does not induce B cell anergy in rats immunized with MIR:

Female Lewis rats were primed with MIR (100 µg/rat) in CFA. Six months later, the rats were divided 5 into three groups of three rats each. One group was treated with saline (control) and the other two groups were treated with MIR-D-EK (100 µg/rat, i.p.) on three successive days. After one week, the rats in the control group and one group that had been treated with MIR-D-EK 10 were boosted with recombinant MIR (1000 µg/rat, i.p.) in saline. One week later, all three groups of rats were bled from the tail vein. The plasma was harvested and assayed for the amount of anti-MIR antibodies by an ELISA assay. Table 2 below reports the data from those assays.

15

Table 2

Group	Treatment	MIR Boost	µg/ml anti-MIR ² (mean ± S.D.)	P vs. Group 1
1	Saline	Yes	130.5 ± 74.7	
20 2	MIR-D-EK	Yes	85.5 ± 31.1	0.195
20 3	MIR-D-EK	No	230.6 ± 31	0.049

25 ² The concentration of anti-MIR antibodies was determined in an ELISA measured against a standard pool of rat anti-MIR sera. The values shown are the mean and standard deviation of the three rats in each group. P values were determined by a Standard t test. Group 2 is not significantly different from Group 1. Group 3 (the non-boosted group) is significantly higher than Group 1.

30 As shown in Table 2, the data on Group 1 animals (saline control) indicate that MIR itself is an immunogen. The data for the Group 2 and 3 animals 35 indicate that the MIR-D-EK conjugate did not affect the

-19-

anti-MIR response. In fact, MIR-D-EK boosted the anti-MIR response in Group 3.

Example 4

5 Tests with Conjugate of L-42 and KLH

These tests, taken together with the results of Example 1 show that the moiety conjugated to D-EK will cause anergy in B cells recognizing that moiety if the moiety either does not contain a T cell epitope or is not 10 recognized by T cells.

Synthesis of L42 peptide-KLH conjugate:

Reduced L-42 (see Example 1) was conjugated to keyhole limpet hemocyanin (KLH) using thioether chemistry similar to that described above with respect to D-EK.

15 L-42 lacks a T cell epitope(s) in mice immunized with L-42-KLH:

Activation of T cells by peptides was measured by the general procedure of Bradley, supra. Female CAF₁ mice were immunized in the footpad with L-42 peptide 20 conjugated KLH (L-42-KLH; 50 µg) in CFA on day 0. On day 7, the popliteal lymph nodes were removed and placed in culture in microtiter plates, at a cell density of 5·10⁵ cells/well. Peptides were added, and, after four days of culture, the wells were pulsed with 1 µCi of tritiated 25 thymidine to measure proliferation of T cells. The cultures were collected after 5 days of culture with a Skatron™ cell harvester. The amount of incorporated ³H-thymidine was determined by scintillation spectrometry. The stimulation index was calculated by dividing the 30 counts incorporated in the absence of peptide. An index of greater than 1 is indicative of the presence of a T cell epitope on the added peptide.

The data in Figure 4 demonstrate that the L-42 did not stimulate the growth of T cells taken from L-42-KLH-immunized mice, and therefore did not contain an 35

-20-

epitope(s) recognized by T-cells induced by immunization with L-42-KLH.

L-42-D-EK conjugate induces a B cell anergy in mice immunized to L-42-KLH:

CAF₁ mice were primed with 100 µg/mouse of L-42-KLH on alum plus B. pertussis vaccine as an adjuvant. Three weeks later, the mice were divided into groups of six mice each. One group was treated by i.p. injections on three successive days with saline (control); the other groups were similarly treated with L-42-KLH (50 µg/mouse, i.p.), and, after a wait of one week, they were bled from the tail vein. The plasma was harvested and assayed for the amount of anti-L-42 and anti-KLH antibodies by ELISA assays. Data are expressed as a percent of a standard serum. An asterisk indicates that a data point was significantly different from the control as determined by a standard t test.

The data in Figure 5 demonstrate that the L-42 response, but not the anti-KLH response, was suppressed in this assay by the L-42-D-EK conjugate. Thus, the studies summarized in Example 1 and these data demonstrate the L-42-D-EK induces B cell anergy when the mice are immunized in a manner that does not induce the proliferation of T cell clones that recognize the L-42 peptide. On the other hand, L-42-D-EK did not induce B cell anergy in animals that were immunized with an immunogen (MIR) which induced T cells that recognized the L-42 peptide.

Modifications of the above-described modes for carrying out the invention that are obvious to those of ordinary skill in the fields of immunology, chemistry, medicine and related arts are unintended to be within the scope of the following claims.

-21-

Claims

1. A composition for inducing specific B cell
5 anergy to an immunogen comprising a conjugate of a
nonimmunogenic biologically stable polymer and an analog
of the immunogen that (a) binds specifically to B cells
to which the immunogen binds specifically and (b) lacks a
T cell epitope.

10

2. The composition of claim 1 wherein the
immunogen is an external immunogen.

15

3. The composition of claim 2 wherein the
external immunogen is a biological drug, an allergen, or
an idiopathic contrast medium.

4. The composition of claim 1 wherein the
immunogen is a self-immunogen.

20

5. The composition of claim 4 wherein the
self immunogen is that associated with thyroiditis,
diabetes, stroke, male infertility, myasthenia gravis,
rheumatic fever, or Rh hemolytic disease.

25

6. The composition of claim 1 wherein the
immunogen and analog are of the same chemical class.

30

7. The composition of claim 6 wherein the
immunogen and the analog are polypeptides.

8. The composition of claim 1 wherein the
immunogen and the analog are of different chemical
classes.

35

-22-

9. The composition of claim 1 wherein the polymer is a copolymer of D-lysine and D-glutamic acid.

10. A method of inducing specific B cell
5 anergy to an immunogen in an individual comprising
administering to the individual an effective amount of
the composition of claims 1, 2, 3, 4, 5, 6, 7, 8 or 9.

11. A method of treating an individual for an
10 antibody-mediated pathology in which undesired antibodies
are produced in response to an immunogen comprising
administering a therapeutically effective amount of the
composition of claims 1, 2, 3, 4, 5, 6, 7, 8 or 9 to the
individual.

15
12. A pharmaceutical composition for treating
an antibody-mediated pathology comprising a
therapeutically effective amount of the conjugate of
claims 1, 2, 3, 4, 5, 6, 7, 8 or 9 combined with a
20 pharmaceutically acceptable carrier.

25

30

35

1/5




FIG. 1

2/5







FIG. 2


3/5

**FIG. 3A**

4/5

**FIG. 4**

5/5



INTERNATIONAL SEARCH REPORT

International Application No. PCT/US92/00976

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)³

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC (5) : A61K 39/00, 39/385

US CL : 424/88

II. FIELDS SEARCHED

Minimum Documentation Searched⁴

Classification System	Classification Symbols
U.S.	424/88

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched⁵

III. DOCUMENTS CONSIDERED TO BE RELEVANT¹⁴

Category ⁶	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
Y	W.E. Paul (ed.), "Fundamental Immunology", published 1989, by Raven Press (NY), pages 571-586. See especially pages 577-579.	1-12
A	R.Arnon (ed.), "Synthetic Vaccines", volume 1, published 1987 by CRC Press (FL), pages 25-37. See entire article	1-12
Y	T.P. Zacharia (ed.), "Immune Response at the Cellular Level", published 1973, by Marcel Dekker, Inc. (NY), pages 141-160. See entire article, especially page 142.	1-12
Y	H. Ginsberg, et al. (eds), "Vaccines 88", published 1988, by Cold Spring Harbor Laboratory, pages 1-7. See abstract.	1-12

* Special categories of cited documents:¹⁵

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search²

02 APRIL 1992

Date of Mailing of this International Search Report²

11 MAY 1992

International Searching Authority¹

ISA/US

Signature of Authorized Officer²⁰

*Deborah F. Nuse, Jr.
Thomas M. Cunningham*